Is Kodak having a "Kodak moment?" 2 watchlist stocks.

Eastman Kodak (KODK) reported 18% YOY revenue growth to $311M, with print and advanced materials segments up 10% and 40% respectively. Gross margin improved 700 bps to 26%, and operational EBITDA grew to $36M. The company is exploring new markets like EV batteries and pharma reagents. NeurAxis (NRXS) also shows potential with high gross margins and product traction.

Original reporting
Published Sep 12, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 7:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is Kodak having a "Kodak moment?" 2 watchlist stocks. — source image
Decision brief

The 30-second read

$KODKBullishLow
01

Why it matters

Both companies show encouraging financial metrics, but scale and sustainability remain uncertain.

02

Market read

Earnings highlight potential upside for turnaround and niche biotech plays, offering modest trading ideas.

03

What to watch

Potential cash flow constraints and reliance on niche markets could limit upside.

Relevance 6/10Novelty 5/10Timing: quarterly results release

Background

Kodak is attempting a turnaround after years of decline, while NeurAxis is a small biotech with recent pricing strength.

Company-level read

Ticker impact

$KODKBullishMedium confidence
Context

Kodak reported Q2 revenue up 18% YoY to $311M with print up 10% and AMC segment up 40%, indicating operational improvement.

Expected impact

Potential modest price appreciation on continued margin expansion.

Evidence & confidence

Revenue and margin growth are material but scale is modest; market may price in incremental upside.

$NRXSBullishMedium confidence
Context

NeurAxis posted 28% YoY price increase and 85.9% gross margin, highlighting strong pricing power and asset efficiency.

Expected impact

Likely continued bullish sentiment, possible short‑term rally.

Evidence & confidence

High gross margin and price growth are encouraging, but company remains small and volatile.

Market effects

Improved performance may lift broader imaging and specialty chemicals sectors.

U.S. small‑cap sentiment could benefit similar niche manufacturers.

Limited; primarily affects U.S. investors focused on turnaround plays.

Counterpoint

Growth may be unsustainable; margin expansion could stall if demand wanes.

Key entities

  • Eastman Kodak Company

    U.S. listed imaging and chemicals firm (KODK).

  • NeurAxis, Inc.

    U.S. listed neuromodulation biotech (NRXS).

Related articles

$KODKHigh

Eastman Kodak (KODK) Q3 2026 Earnings Call Transcript

Eastman Kodak (KODK) reported Q3 2026 earnings with revenue of $276M, up 3% YoY, driven by 21% growth in Advanced Materials and Chemicals (AMC). Gross profit increased 7% to $73M, and operational EBITDA rose 7% to $31M. AMC now accounts for 36% of revenue and over half of operational EBITDA. Print revenues declined 7% due to raw material challenges and competitive pressures. The company generated $27M in cash for the quarter.

$KODKMed

Eastman Kodak Q3 Earnings Call Highlights

Eastman Kodak reported Q3 print revenue decline of 7% to $165M, citing raw-material prices and competition. However, AM&C segment grew 21%, driving 9% revenue increase to $852M for the first nine months. Gross profit rose 28% to $212M, with net income at $22M vs. a prior-year loss. Kodak reaffirmed commitment to print and AM&C, with $317M in unrestricted cash and $400M debt reduction year-over-year.

$KODKMedAI 8/10

Eastman Kodak Co (KODK) (Q3 2026) Earnings Call Highlights: Advanced Materials Surge

Eastman Kodak (KODK) reported Q3 2026 earnings with $317M unrestricted cash, up $27M from June 2026. Operational EBITDA rose to $31M, up $2M YoY. Print revenue declined 7% due to material costs and competition. GAAP net income increased 62% to $21M. Debt reduced by $400M, including $101M in term loan repayments. Year-to-date revenue up 9% to $852M, with growth in all segments. AMC segment led with 21% growth. Gross profit rose 28% to $212M, and net income improved $42M YoY.